Charged Alpha logo
CHARGED ALPHA
Stock Analysis
Home Shows Games YouTube
Tools
Stock Screener Stocks Mutual Funds Funds ETF Screener ETFs Crypto Screener Crypto Options Scanner Options Bond Dashboard Rates REIT Screener REITs Forex Heatmap FX Commodities Futures Earnings Calendar Reports Precious Metals Metals Stock Charts Charts
Stock Library / TAK
TAK Unclassified Latest YouTube: Q1 FY2026 Published 2026-07-30

TAK

Live stock metrics, chart context, a quarter-by-quarter episode archive, and a deeper competitor comparison so this page behaves more like an investor workspace than a flat episode link page.

Latest on YouTube Latest on Podbean Apple Podcasts Amazon Music iHeartRadio YouTube Music Company Website Back to Library

Latest earnings video

Takeda (TAK): 11.6x Core Earnings or 52.8x Reported? The 740 Billion Yen Gap

Published 2026-07-30

Open YouTube Spotify Show Open Podbean Apple Podcasts

Library coverage

Episodes tracked
1
Episodes linked
1
Latest video
Q1 FY2026
2026-07-30
Podcast available
Yes
Current price
$17.09
-0.41 (-2.34%)
Trailing / Forward P/E
—
Forward: 32.25x
Market cap / Volume
—
Volume: —
Revenue / Earnings Growth
10.2%
Earnings: -9.8%
Margins
16.4% op
Gross: 64.5% · Net: -3.5%
Balance sheet
1.14x current
Debt / Equity: 73.2
52-week range / Beta
$12.99 - $18.90
Beta: 0.09
Analyst target
$21.78
Upside: 27.4%
Cash / shareholder return
992.07% FCF yield
Dividend yield: 11.59%

Company context

Industry: Drug Manufacturers - Specialty & Generic
Country: Japan
Employees: —
Price to book: 1.19x
Return on equity: -2.3%
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Takhzyro, Advate, Elaprase, Replagal, Vpriv, Adynovate/Adynovi, Livtencity, ADZYNMA, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Flexbumin, Adcetris, Leuplin/Enantone, Ninlaro, Iclusig, FRUZAQLA, Alunbrig, vyvanse/elvanse, Trintellix, and QDENGA brands. It has licensing and collaboration for the development and commercialization of products with Arrowhead Pharmaceuticals, Cour Pharmaceuticals, Engitix, Halozyme, Mirum Pharmaceuticals, Ucsd/Fortis Advisors, Zedira/Dr. Falk Pharma, Ac Immune, Acurastem, Anima Biotech, Biomarin, Denali Therapeutics, Luxna Biotech, Neurocrine Biosciences, Peptidream, Abbvie, Adimab, Ascentage Pharma, Crescendo Biologics, Exelixis, F-Star, Gsk, Heidelberg Pharma, Innovent Biologics, Keros Therapeutics, Kumquat Biosciences, Protagonist Therapeutics, Halozyme, Kamada, Johnson & Johnson/Momenta Pharmaceuticals, Previpharma, Novavax, Bridgene Biosciences, Charles River Laboratories, Iambic Therapeutics, Ipsen, Km Biologics, Massachusetts Institute Of Technology, and Nabla Bio. The company operates in Japan, the United States. Europe, Canada, Latin America, China, Asia, Russia/Commonwealth of Independent States, the Middle East, Oceania, and Africa. The company was founded in 1781 and is headquartered in Chuo, Japan.

Price chart

Market context for TAK

Competitive view

TAK vs. two close competitors

This section compares the current company against two nearby peers on valuation, growth, margins, balance-sheet strength, and investment setup. Green generally marks the strongest relative figure for that row, while red marks the weakest.

TAK latest YouTube video thumbnail YouTube
TAK
TAK
YouTube Podbean
Latest video
Q1 FY2026
Growth is positive but not explosive, which usually supports a steadier compounding case than a hyper-growth story.
Cash generation stands out versus market value, which helps the stock absorb valuation pressure better than weaker cash converters.
Valuation already asks investors to pay up, so the upside case depends on continued execution staying strong.
Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.
SS&C Technologies Holdings Inc. latest YouTube video thumbnail YouTube
SS&C Technologies Holdings Inc.
SSNC
YouTube Podbean
Latest video
Q2 2026
Growth profile looks strong right now, with above-average top-line and/or earnings momentum.
Cash generation stands out versus market value, which helps the stock absorb valuation pressure better than weaker cash converters.
Valuation looks more grounded than many growth names, which can improve the risk/reward if fundamentals hold up.
Balance-sheet leverage is elevated, so investors should watch refinancing costs and how much flexibility management really has.
Danaher Corporation latest YouTube video thumbnail YouTube
Danaher Corporation
DHR
YouTube Podbean
Latest video
Q2 2026
Growth profile looks strong right now, with above-average top-line and/or earnings momentum.
Cash generation stands out versus market value, which helps the stock absorb valuation pressure better than weaker cash converters.
Valuation sits in a middle zone where future upside likely depends more on quarterly execution than on multiple re-rating alone.
Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.
Market Cap
More scale can mean deeper resources and resilience, although bigger does not automatically mean better upside.
TAK
$54.58B
TAK
SSNC
$18.56B
SS&C Technologies Holdings Inc.
DHR
$137.07B
Danaher Corporation
Trailing P/E
Lower trailing P/E can indicate a cheaper valuation relative to trailing earnings, but it may also reflect slower growth or higher perceived risk.
TAK
—
TAK
SSNC
22.1x
SS&C Technologies Holdings Inc.
DHR
34.8x
Danaher Corporation
Forward P/E
Forward P/E is often a better read on what investors are paying for the next year of earnings power.
TAK
32.2x
TAK
SSNC
10.0x
SS&C Technologies Holdings Inc.
DHR
21.0x
Danaher Corporation
Revenue Growth
Higher revenue growth usually signals stronger demand, market share gains, or a business still in expansion mode.
TAK
10.2%
TAK
SSNC
10.3%
SS&C Technologies Holdings Inc.
DHR
5.5%
Danaher Corporation
Earnings Growth
Faster earnings growth matters because it shows management is converting sales momentum into shareholder value.
TAK
-9.8%
TAK
SSNC
34.7%
SS&C Technologies Holdings Inc.
DHR
59.7%
Danaher Corporation
Operating Margin
Higher operating margin suggests better operating discipline, pricing power, or a structurally stronger business model.
TAK
16.4%
TAK
SSNC
24.6%
SS&C Technologies Holdings Inc.
DHR
19.8%
Danaher Corporation
Gross Margin
Gross margin helps show how much product-level pricing power and unit economics a company has before overhead.
TAK
64.5%
TAK
SSNC
48.1%
SS&C Technologies Holdings Inc.
DHR
58.8%
Danaher Corporation
Net Margin
Higher net margin means more of each dollar of revenue reaches the bottom line after all costs.
TAK
-3.5%
TAK
SSNC
13.2%
SS&C Technologies Holdings Inc.
DHR
15.9%
Danaher Corporation
Return on Equity
ROE shows how efficiently management turns shareholder capital into profits, though leverage can inflate it.
TAK
-2.3%
TAK
SSNC
12.6%
SS&C Technologies Holdings Inc.
DHR
7.6%
Danaher Corporation
Free Cash Flow Yield
Higher free cash flow yield can indicate a stronger cash return relative to the stock's market value.
TAK
992.1%
TAK
SSNC
7.0%
SS&C Technologies Holdings Inc.
DHR
3.2%
Danaher Corporation
Debt to Equity
Lower leverage usually means less balance-sheet risk, though capital-intensive sectors naturally run higher debt loads.
TAK
73.25x
TAK
SSNC
115.90x
SS&C Technologies Holdings Inc.
DHR
52.97x
Danaher Corporation
Current Ratio
A stronger current ratio usually signals better short-term liquidity and more room to absorb shocks.
TAK
1.14x
TAK
SSNC
1.06x
SS&C Technologies Holdings Inc.
DHR
1.65x
Danaher Corporation
Beta
Lower beta often means lower volatility versus the market, while higher beta usually brings a rougher ride.
TAK
0.09
TAK
SSNC
1.11
SS&C Technologies Holdings Inc.
DHR
0.82
Danaher Corporation
Dividend Yield
Dividend yield matters for income-focused investors, but a high yield can also reflect a stressed stock price.
TAK
11.6%
TAK
SSNC
0.7%
SS&C Technologies Holdings Inc.
DHR
0.7%
Danaher Corporation
Analyst Upside
Higher analyst upside suggests the Street still sees room between current price and consensus fair value.
TAK
27.4%
TAK
SSNC
19.8%
SS&C Technologies Holdings Inc.
DHR
16.9%
Danaher Corporation

Related research

Non-quarter videos featuring TAK

Special-topic videos, explainers, and shorts connected to this ticker.

All Research Sections
Shorts and Clips 2026-07-30

Takeda (TAK): 11.6x Core or 52.8x Reported? #shorts

A fast Charged Alpha clip pointing viewers into the latest earnings coverage.

YouTube

Episode timeline

Episode archive for TAK

Each row is one earnings episode with every verified platform link available.

Q1 FY2026
Episode live
2026-07-30
Published youtube podcast complete
Takeda (TAK): 11.6x Core Earnings or 52.8x Reported? The 740 Billion Yen Gap
Quarterly earnings-analysis entry for TAK. Use the links on the right to open the video or podcast episode.
YouTube Spotify Show Podcast Apple Podcasts Amazon Show iHeart Show YouTube Music